Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Autoimmune Disorders

  Free Subscription


Articles published in Neurology

Retrieve available abstracts of 270 articles:
HTML format
Text format



Single Articles


    June 2018
  1. VITT JR, Kreple C, Mahmood N, Dickerson E, et al
    Autoimmune pancerebellitis associated with pembrolizumab therapy.
    Neurology. 2018 Jun 6. pii: WNL.0000000000005781.
    PubMed     Text format    


  2. PROSPERINI L, Lucchini M, Haggiag S, Bellantonio P, et al
    Fingolimod vs dimethyl fumarate in multiple sclerosis: A real-world propensity score-matched study.
    Neurology. 2018 Jun 6. pii: WNL.0000000000005772.
    PubMed     Text format     Abstract available


    May 2018
  3. LEHMANN HC, Compston A, Hartung HP
    150th anniversary of clinical description of multiple sclerosis: Leopold Ordenstein's legacy.
    Neurology. 2018;90:1011-1016.
    PubMed     Text format     Abstract available


  4. KIM DD, Ho C, King R, Morrow SA, et al
    Pearls & Oy-sters: An unusual neuropsychiatric manifestation of systemic lupus erythematosus.
    Neurology. 2018;90:e1929-e1932.
    PubMed     Text format    


  5. LIEWLUCK T
    Author response: Anti-cytosolic 5'-nucleotidase 1A (cN1A) autoantibodies in motor neuron diseases.
    Neurology. 2018;90:990.
    PubMed     Text format    


  6. BUDHRAM A
    Reader response: Anti-cytosolic 5'-nucleotidase 1A (cN1A) autoantibodies in motor neuron diseases.
    Neurology. 2018;90:990.
    PubMed     Text format    


  7. KARAM C, Galetta S
    Editors' note: Anti-cytosolic 5'-nucleotidase 1A (cN1A) autoantibodies in motor neuron diseases.
    Neurology. 2018;90:989.
    PubMed     Text format    


  8. SCALFARI A, Romualdi C, Nicholas RS, Mattoscio M, et al
    The cortical damage, early relapses, and onset of the progressive phase in multiple sclerosis.
    Neurology. 2018 May 16. pii: WNL.0000000000005685.
    PubMed     Text format     Abstract available


  9. DE LORENZO R, Pinal-Fernandez I, Huang W, Albayda J, et al
    Muscular and extramuscular clinical features of patients with anti-PM/Scl autoantibodies.
    Neurology. 2018 May 4. pii: WNL.0000000000005638.
    PubMed     Text format     Abstract available


  10. FRANKLIN GM, McDonnell G
    Free health care, great data, and new clues on multiple sclerosis.
    Neurology. 2018 May 2. pii: WNL.0000000000005593.
    PubMed     Text format    


  11. LOPEZ CHIRIBOGA AS, Matsumoto J, Sorenson E, Klein CJ, et al
    Teaching Video NeuroImages: Acquired focal neuromyotonia in LGI-1 autoimmunity.
    Neurology. 2018;90:e1636-e1637.
    PubMed     Text format    


    April 2018
  12. GERARDI C, Bertele' V, Rossi S, Garattini S, et al
    Preapproval and postapproval evidence on drugs for multiple sclerosis.
    Neurology. 2018 Apr 25. pii: WNL.0000000000005561.
    PubMed     Text format     Abstract available


  13. BAR-OR A, Grove RA, Austin DJ, Tolson JM, et al
    Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study.
    Neurology. 2018 Apr 25. pii: WNL.0000000000005516.
    PubMed     Text format     Abstract available


  14. COBO-CALVO A, Ruiz A, Maillart E, Audoin B, et al
    Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: The MOGADOR study.
    Neurology. 2018 Apr 25. pii: WNL.0000000000005560.
    PubMed     Text format     Abstract available


  15. RAE-GRANT A, Day GS, Marrie RA, Rabinstein A, et al
    Comprehensive systematic review summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
    Neurology. 2018;90:789-800.
    PubMed     Text format     Abstract available


  16. RAE-GRANT A, Day GS, Marrie RA, Rabinstein A, et al
    Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
    Neurology. 2018;90:777-788.
    PubMed     Text format     Abstract available


  17. HEWETT K, Sanders DB, Grove RA, Broderick CL, et al
    Randomized study of adjunctive belimumab in participants with generalized myasthenia gravis.
    Neurology. 2018;90:e1425-e1434.
    PubMed     Text format     Abstract available


  18. PEDROSO JL, Dutra LA, Espay AJ, Hoftberger R, et al
    Video NeuroImages: Head titubation in anti-mGluR1 autoantibody-associated cerebellitis.
    Neurology. 2018;90:746-747.
    PubMed     Text format    


  19. CORREALE J, Ysrraelit MC, Benarroch EE
    Metabolic coupling of axons and glial cells: Implications for multiple sclerosis progression.
    Neurology. 2018;90:737-744.
    PubMed     Text format    


    March 2018
  20. FERRARO D, Camera V, Vitetta F, Zennaro M, et al
    Acute coronary syndrome associated with alemtuzumab infusion in multiple sclerosis.
    Neurology. 2018 Mar 30. pii: WNL.0000000000005417.
    PubMed     Text format    


  21. SAARELA M, Senthil K, Jones J, Tienari PJ, et al
    Hemophagocytic lymphohistiocytosis in 2 patients with multiple sclerosis treated with alemtuzumab.
    Neurology. 2018 Mar 30. pii: WNL.0000000000005420.
    PubMed     Text format    


  22. ROTSTEIN DL, Chen H, Wilton AS, Kwong JC, et al
    Temporal trends in multiple sclerosis prevalence and incidence in a large population.
    Neurology. 2018 Mar 16. pii: WNL.0000000000005331.
    PubMed     Text format     Abstract available


  23. GAETANO L, Haring DA, Radue EW, Mueller-Lenke N, et al
    Fingolimod effect on gray matter, thalamus, and white matter in patients with multiple sclerosis.
    Neurology. 2018 Mar 14. pii: WNL.0000000000005292.
    PubMed     Text format     Abstract available


  24. SCHOONHEIM MM, Ciccarelli O
    The value of including thalamic atrophy as a clinical trial endpoint in multiple sclerosis.
    Neurology. 2018 Mar 14. pii: WNL.0000000000005279.
    PubMed     Text format    


  25. MCKAY KA, Tremlett H, Fisk JD, Zhang T, et al
    Psychiatric comorbidity is associated with disability progression in multiple sclerosis.
    Neurology. 2018 Mar 9. pii: WNL.0000000000005302.
    PubMed     Text format     Abstract available


  26. MILLER AE, Calabresi PA
    Central vein sign in multiple sclerosis: Ready for front and center?
    Neurology. 2018 Mar 7. pii: WNL.0000000000005241.
    PubMed     Text format    


  27. TREMLETT H, Zhu F, Ascherio A, Munger KL, et al
    Sun exposure over the life course and associations with multiple sclerosis.
    Neurology. 2018 Mar 7. pii: WNL.0000000000005257.
    PubMed     Text format     Abstract available


    February 2018
  28. CHATAWAY J, Martin K, Barrell K, Sharrack B, et al
    Effects of ATX-MS-1467 immunotherapy over 16 weeks in relapsing multiple sclerosis.
    Neurology. 2018 Feb 21. pii: WNL.0000000000005118.
    PubMed     Text format     Abstract available


  29. PORTACCIO E, Annovazzi P, Ghezzi A, Zaffaroni M, et al
    Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks.
    Neurology. 2018 Feb 7. pii: WNL.0000000000005067.
    PubMed     Text format     Abstract available


  30. PORTACCIO E, Moiola L, Martinelli V, Annovazzi P, et al
    Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: II: Maternal risks.
    Neurology. 2018 Feb 7. pii: WNL.0000000000005068.
    PubMed     Text format     Abstract available


  31. ALROUGHANI R, Alowayesh MS, Ahmed SF, Behbehani R, et al
    Relapse occurrence in women with multiple sclerosis during pregnancy in the new treatment era.
    Neurology. 2018 Feb 2. pii: WNL.0000000000005065.
    PubMed     Text format     Abstract available


    January 2018
  32. BENNETT S, Leavitt VM
    An intervention to improve balance in persons with multiple sclerosis.
    Neurology. 2018 Jan 31. pii: WNL.0000000000005038.
    PubMed     Text format    


  33. HEBERT JR, Corboy JR, Vollmer T, Forster JE, et al
    Efficacy of Balance and Eye-Movement Exercises for Persons With Multiple Sclerosis (BEEMS).
    Neurology. 2018 Jan 31. pii: WNL.0000000000005013.
    PubMed     Text format     Abstract available


  34. WEHRUM T, Beume LA, Stich O, Mader I, et al
    Activation of disease during therapy with alemtuzumab in 3 patients with multiple sclerosis.
    Neurology. 2018 Jan 19. pii: WNL.0000000000004950.
    PubMed     Text format     Abstract available


  35. PETERSEN ER, Oturai AB, Koch-Henriksen N, Magyari M, et al
    Smoking affects the interferon beta treatment response in multiple sclerosis.
    Neurology. 2018 Jan 17. pii: WNL.0000000000004949.
    PubMed     Text format     Abstract available


  36. SUMOWSKI JF, Benedict R, Enzinger C, Filippi M, et al
    Cognition in multiple sclerosis: State of the field and priorities for the future.
    Neurology. 2018 Jan 17. pii: WNL.0000000000004977.
    PubMed     Text format     Abstract available


  37. ALLENBACH Y, Arouche-Delaperche L, Preusse C, Radbruch H, et al
    Necrosis in anti-SRP(+) and anti-HMGCR(+)myopathies: Role of autoantibodies and complement.
    Neurology. 2018 Jan 12. pii: WNL.0000000000004923.
    PubMed     Text format     Abstract available


  38. ZHANG T, Tremlett H, Zhu F, Kingwell E, et al
    Effects of physical comorbidities on disability progression in multiple sclerosis.
    Neurology. 2018 Jan 3. pii: WNL.0000000000004885.
    PubMed     Text format     Abstract available


    December 2017
  39. PISA M, Guerrieri S, Di Maggio G, Medaglini S, et al
    No evidence of disease activity is associated with reduced rate of axonal retinal atrophy in MS.
    Neurology. 2017;89:2469-2475.
    PubMed     Text format     Abstract available


  40. DUBEY D, Lennon VA, Gadoth A, Pittock SJ, et al
    Autoimmune CRMP5 neuropathy phenotype and outcome defined from 105 cases.
    Neurology. 2017 Dec 8. pii: WNL.0000000000004803.
    PubMed     Text format     Abstract available


  41. LOREFICE L, Fenu G, Gerevini S, Frau J, et al
    PML in a person with multiple sclerosis: Is teriflunomide the felon?
    Neurology. 2017 Dec 6. pii: WNL.0000000000004804.
    PubMed     Text format    


  42. FITZGERALD KC, Tyry T, Salter A, Cofield SS, et al
    Diet quality is associated with disability and symptom severity in multiple sclerosis.
    Neurology. 2017 Dec 6. pii: WNL.0000000000004768.
    PubMed     Text format     Abstract available


  43. SUMOWSKI JF, McDonnell GV, Bourdette D
    Diet in multiple sclerosis: Science takes a seat at the table.
    Neurology. 2017 Dec 6. pii: WNL.0000000000004775.
    PubMed     Text format    


    November 2017
  44. BURNOR E, Yang L, Zhou H, Patterson KR, et al
    Neurofascin antibodies in autoimmune, genetic, and idiopathic neuropathies.
    Neurology. 2017 Nov 29. pii: WNL.0000000000004773.
    PubMed     Text format     Abstract available


  45. KLAWITER EC, Bove R, Elsone L, Alvarez E, et al
    High risk of postpartum relapses in neuromyelitis optica spectrum disorder.
    Neurology. 2017;89:2238-2244.
    PubMed     Text format     Abstract available


  46. LARONI A, Signori A, Maniscalco GT, Lanzillo R, et al
    Assessing association of comorbidities with treatment choice and persistence in MS: A real-life multicenter study.
    Neurology. 2017;89:2222-2229.
    PubMed     Text format     Abstract available


  47. KARCESKI S
    How comorbid conditions affect the choice of treatment in multiple sclerosis.
    Neurology. 2017;89:e265-e267.
    PubMed     Text format    


  48. DHAWAN PS, Dyck PJB, Tracy JA, Naddaf E, et al
    Systemic vasculitis with dermatomyositis, hearing loss, neuropathy, and multiorgan dysfunction.
    Neurology. 2017;89:2119-2120.
    PubMed     Text format    


  49. KOWALEC K, McKay KA, Patten SB, Fisk JD, et al
    Comorbidity increases the risk of relapse in multiple sclerosis: A prospective study.
    Neurology. 2017 Nov 8. pii: 10.1212/WNL.0000000000004716.
    PubMed     Text format     Abstract available


  50. BURMAN J, Zelano J
    Epilepsy in multiple sclerosis: A nationwide population-based register study.
    Neurology. 2017 Nov 8. pii: 10.1212/WNL.0000000000004740.
    PubMed     Text format     Abstract available


  51. HOUZEN H, Kondo K, Niino M, Horiuchi K, et al
    Prevalence and clinical features of neuromyelitis optica spectrum disorders in northern Japan.
    Neurology. 2017;89:1995-2001.
    PubMed     Text format     Abstract available


  52. ARRAMBIDE G, Tintore M, Auger C, Rio J, et al
    Lesion topographies in multiple sclerosis diagnosis: A reappraisal.
    Neurology. 2017 Nov 3. pii: 10.1212/WNL.0000000000004715.
    PubMed     Text format     Abstract available


  53. BARNETT C, Bril V, Kapral M, Kulkarni AV, et al
    Myasthenia Gravis Impairment Index: Responsiveness, meaningful change, and relative efficiency.
    Neurology. 2017 Nov 3. pii: 10.1212/WNL.0000000000004676.
    PubMed     Text format     Abstract available


    October 2017
  54. NOVAKOVA L, Zetterberg H, Sundstrom P, Axelsson M, et al
    Monitoring disease activity in multiple sclerosis using serum neurofilament light protein.
    Neurology. 2017 Oct 27. pii: 10.1212/WNL.0000000000004683.
    PubMed     Text format     Abstract available


  55. CHIANG S, Kesari NK, Bradshaw A, Chen W, et al
    Pearls & Oy-sters: CNS lymphoma in a patient with relapsing-remitting multiple sclerosis treated with interferon.
    Neurology. 2017;89:e210-e213.
    PubMed     Text format    


  56. MATHIS S, Magy L, Le Masson G, Vallat JM, et al
    Did Jules Dejerine describe AMAN at the end of the 19th century?
    Neurology. 2017;89:1749-1753.
    PubMed     Text format     Abstract available


  57. KARGIOTIS O, Safouris A, Petrou VN, Magoufis G, et al
    Teaching NeuroImages: Giant cell arteritis presenting with acute ischemic strokes due to diffuse intracranial stenoses.
    Neurology. 2017;89:e190-e191.
    PubMed     Text format    


  58. TSIVGOULIS G, Papadimitropoulos GN, Katsanos AH, Zompola C, et al
    Teaching NeuroImages: Interferon-induced psoriasis flare in a multiple sclerosis case remits with dimethyl fumarate.
    Neurology. 2017;89:e188-e189.
    PubMed     Text format    


  59. MUNGER KL, Hongell K, Aivo J, Soilu-Hanninen M, et al
    25-Hydroxyvitamin D deficiency and risk of MS among women in the Finnish Maternity Cohort.
    Neurology. 2017;89:1578-1583.
    PubMed     Text format     Abstract available


    September 2017
  60. LIEWLUCK T
    Anti-cytosolic 5'-nucleotidase 1A (cN1A) autoantibodies in motor neuron diseases.
    Neurology. 2017 Sep 27. pii: 10.1212/WNL.0000000000004610.
    PubMed     Text format    


  61. KARCESKI S
    Multiple sclerosis, inflammation in the brain, and mood.
    Neurology. 2017;89:e169-e171.
    PubMed     Text format    


  62. MARRIE RA, Salter A, Tyry T, Cutter GR, et al
    Author response: High hypothetical interest in physician-assisted death in multiple sclerosis.
    Neurology. 2017;89:1429-1430.
    PubMed     Text format    


  63. SETHI NK
    Letter re: High hypothetical interest in physician-assisted death in multiple sclerosis and Physician-assisted death in chronic neurologic diseases.
    Neurology. 2017;89:1429.
    PubMed     Text format    


  64. MASDEU JC
    Letter re: High hypothetical interest in physician-assisted death in multiple sclerosis.
    Neurology. 2017;89:1428.
    PubMed     Text format    


  65. THORMANN A, Sorensen PS, Koch-Henriksen N, Laursen B, et al
    Comorbidity in multiple sclerosis is associated with diagnostic delays and increased mortality.
    Neurology. 2017 Sep 20. pii: 10.1212/WNL.0000000000004508.
    PubMed     Text format     Abstract available


  66. PLAVINA T, Muralidharan KK, Kuesters G, Mikol D, et al
    Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients.
    Neurology. 2017 Sep 15. pii: 10.1212/WNL.0000000000004485.
    PubMed     Text format     Abstract available


  67. MARRIE RA, Beck CA
    Preventing multiple sclerosis: To (take) vitamin D or not to (take) vitamin D?
    Neurology. 2017 Sep 13. pii: 10.1212/WNL.0000000000004506.
    PubMed     Text format    


  68. LOPEZ-CHIRIBOGA AS, Clardy SL
    Emerging Subspecialties in Neurology: Autoimmune neurology.
    Neurology. 2017;89:e129-e133.
    PubMed     Text format    


  69. FILLI L, Zorner B, Killeen T, Linnebank M, et al
    Author response: Monitoring long-term efficacy of fampridine in gait-impaired patients with multiple sclerosis.
    Neurology. 2017;89:1200.
    PubMed     Text format    


  70. DAVIS FA
    Letter re: Monitoring long-term efficacy of fampridine in gait-impaired patients with multiple sclerosis.
    Neurology. 2017;89:1199.
    PubMed     Text format    


  71. COLES AJ, Cohen JA, Fox EJ, Giovannoni G, et al
    Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings.
    Neurology. 2017;89:1117-1126.
    PubMed     Text format     Abstract available


  72. HAVRDOVA E, Arnold DL, Cohen JA, Hartung HP, et al
    Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy.
    Neurology. 2017;89:1107-1116.
    PubMed     Text format     Abstract available


  73. LORSCHEIDER J, Jokubaitis VG, Spelman T, Izquierdo G, et al
    Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS.
    Neurology. 2017;89:1050-1059.
    PubMed     Text format     Abstract available


    August 2017
  74. LANGER-GOULD A, Wu J, Lucas R, Smith J, et al
    Epstein-Barr virus, cytomegalovirus, and multiple sclerosis susceptibility: A multiethnic study.
    Neurology. 2017 Aug 30. pii: 10.1212/WNL.0000000000004412.
    PubMed     Text format     Abstract available


  75. HENNES EM, Baumann M, Schanda K, Anlar B, et al
    Prognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome.
    Neurology. 2017;89:900-908.
    PubMed     Text format     Abstract available


  76. ROSSI S, Studer V, Motta C, Polidoro S, et al
    Neuroinflammation drives anxiety and depression in relapsing-remitting multiple sclerosis.
    Neurology. 2017 Aug 25. pii: 10.1212/WNL.0000000000004411.
    PubMed     Text format     Abstract available


  77. KOCH-HENRIKSEN N, Lauer K
    Dietary sodium intake: An etiologic dead end in multiple sclerosis.
    Neurology. 2017 Aug 25. pii: 10.1212/WNL.0000000000004426.
    PubMed     Text format    


  78. CORTESE M, Yuan C, Chitnis T, Ascherio A, et al
    No association between dietary sodium intake and the risk of multiple sclerosis.
    Neurology. 2017 Aug 25. pii: 10.1212/WNL.0000000000004417.
    PubMed     Text format     Abstract available


  79. WIENDL H, Bourdette D, Ciccarelli O
    Can immune reprogramming with alemtuzumab induce permanent remission in multiple sclerosis?
    Neurology. 2017 Aug 23. pii: 10.1212/WNL.0000000000004381.
    PubMed     Text format    


  80. DE MEO E, Moiola L, Ghezzi A, Veggiotti P, et al
    MRI substrates of sustained attention system and cognitive impairment in pediatric MS patients.
    Neurology. 2017 Aug 18. pii: 10.1212/WNL.0000000000004388.
    PubMed     Text format     Abstract available


  81. SUZUKI S, Ishikawa N, Konoeda F, Seki N, et al
    Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan.
    Neurology. 2017 Aug 18. pii: 10.1212/WNL.0000000000004359.
    PubMed     Text format     Abstract available


  82. BEECHER G, Anderson D, Siddiqi ZA
    Subcutaneous immunoglobulin in myasthenia gravis exacerbation: A prospective, open-label trial.
    Neurology. 2017 Aug 16. pii: 10.1212/WNL.0000000000004365.
    PubMed     Text format     Abstract available



  83. Escalation therapy for multiple sclerosis in Austria: Analysis of gender differences in the nationwide registry.
    Neurology. 2017;89:752.
    PubMed     Text format    


  84. HEHIR MK, Hobson-Webb LD, Benatar M, Barnett C, et al
    Rituximab as treatment for anti-MuSK myasthenia gravis: Multicenter blinded prospective review.
    Neurology. 2017 Aug 11. pii: 10.1212/WNL.0000000000004341.
    PubMed     Text format     Abstract available


    July 2017
  85. NIELSEN NM, Munger KL, Stenager E, Ascherio A, et al
    Author response: Neonatal vitamin D status and risk of multiple sclerosis: A population-based case-control study.
    Neurology. 2017;89:411.
    PubMed     Text format    


  86. XIA Z, Cheng Q, Li J
    Letter re: Neonatal vitamin D status and risk of multiple sclerosis: A population-based case-control study.
    Neurology. 2017;89:410-411.
    PubMed     Text format    


  87. ZARGHAMI A
    Letter re: Neonatal vitamin D status and risk of multiple sclerosis: A population-based case-control study.
    Neurology. 2017;89:410.
    PubMed     Text format    


  88. MARANZANO J, Rudko DA, Nakamura K, Cook S, et al
    MRI evidence of acute inflammation in leukocortical lesions of patients with early multiple sclerosis.
    Neurology. 2017 Jul 19. pii: 10.1212/WNL.0000000000004227.
    PubMed     Text format     Abstract available


  89. HACOHEN Y, Mankad K, Chong WK, Barkhof F, et al
    Diagnostic algorithm for relapsing acquired demyelinating syndromes in children.
    Neurology. 2017;89:269-278.
    PubMed     Text format     Abstract available


  90. LANGER-GOULD A, Smith JB, Hellwig K, Gonzales E, et al
    Breastfeeding, ovulatory years, and risk of multiple sclerosis.
    Neurology. 2017 Jul 12. pii: 10.1212/WNL.0000000000004207.
    PubMed     Text format     Abstract available



  91. Autologous hematopoietic stem cell transplantation in multiple sclerosis: A meta-analysis.
    Neurology. 2017;89:215.
    PubMed     Text format    


  92. URUHA A, Suzuki S, Nishino I
    Author update: Sarcoplasmic MxA expression: A valuable marker of dermatomyositis.
    Neurology. 2017;89:215.
    PubMed     Text format    


  93. BURKILL S, Montgomery S, Hajiebrahimi M, Hillert J, et al
    Mortality trends for multiple sclerosis patients in Sweden from 1968 to 2012.
    Neurology. 2017 Jul 7. pii: 10.1212/WNL.0000000000004216.
    PubMed     Text format     Abstract available


    June 2017
  94. LEWIS EJH, Perkins BA, Lovblom LE, Bazinet RP, et al
    Effect of omega-3 supplementation on neuropathy in type 1 diabetes: A 12-month pilot trial.
    Neurology. 2017;88:2294-2301.
    PubMed     Text format     Abstract available


  95. DE JONG HJI, Kingwell E, Shirani A, Cohen Tervaert JW, et al
    Evaluating the safety of beta-interferons in MS: A series of nested case-control studies.
    Neurology. 2017;88:2310-2320.
    PubMed     Text format     Abstract available


  96. BRENNA G, Antozzi C, Montomoli C, Baggi F, et al
    A propensity score analysis for comparison of T-3b and VATET in myasthenia gravis.
    Neurology. 2017 Jun 7. pii: 10.1212/WNL.0000000000004082.
    PubMed     Text format     Abstract available


    May 2017
  97. BATISTA S, Alves C, d'Almeida OC, Afonso A, et al
    Disconnection as a mechanism for social cognition impairment in multiple sclerosis.
    Neurology. 2017 May 31. pii: 10.1212/WNL.0000000000004060.
    PubMed     Text format     Abstract available


  98. SOLOMON AJ, Weinshenker BG
    Author response: The contemporary spectrum of multiple sclerosis misdiagnosis: A multicenter study.
    Neurology. 2017;88:2067-2068.
    PubMed     Text format    


  99. DALLA COSTA G, Martinelli V, Comi G
    Letter re: The contemporary spectrum of multiple sclerosis misdiagnosis: A multicenter study.
    Neurology. 2017;88:2067.
    PubMed     Text format    


  100. ESHAGHI A, Ciccarelli O
    Author response: Gray matter MRI differentiates neuromyelitis optica from multiple sclerosis using random forest.
    Neurology. 2017;88:1875.
    PubMed     Text format    


  101. AVASARALA J
    Letter re: Gray matter MRI differentiates neuromyelitis optica from multiple sclerosis using random forest.
    Neurology. 2017;88:1875.
    PubMed     Text format    


  102. TIMMINGS PL, Siu R, Bukhari W, Todd A, et al
    Author response: Acute Zika infection with concurrent onset of Guillain-BarrE syndrome.
    Neurology. 2017;88:1874-1875.
    PubMed     Text format    


  103. GERARDIN P, Cao-Lormeau VM, Tournebize P, Cerny T, et al
    Letter re: Acute Zika infection with concurrent onset of Guillain-BarrE syndrome.
    Neurology. 2017;88:1874.
    PubMed     Text format    


  104. MEIJER KA, Eijlers AJC, Douw L, Uitdehaag BMJ, et al
    Increased connectivity of hub networks and cognitive impairment in multiple sclerosis.
    Neurology. 2017 May 3. pii: 10.1212/WNL.0000000000003982.
    PubMed     Text format     Abstract available


  105. AUBERT-BROCHE B, Weier K, Longoni G, Fonov VS, et al
    Monophasic demyelination reduces brain growth in children.
    Neurology. 2017;88:1744-1750.
    PubMed     Text format     Abstract available


  106. GAIG C, Graus F, Compta Y, Hogl B, et al
    Clinical manifestations of the anti-IgLON5 disease.
    Neurology. 2017;88:1736-1743.
    PubMed     Text format     Abstract available


    April 2017
  107. SORMANI MP, Muraro PA, Schiavetti I, Signori A, et al
    Autologous hematopoietic stem cell transplantation in multiple sclerosis: A meta-analysis.
    Neurology. 2017 Apr 28. pii: 10.1212/WNL.0000000000003987.
    PubMed     Text format     Abstract available


  108. GIANFRANCESCO MA, Stridh P, Rhead B, Shao X, et al
    Evidence for a causal relationship between low vitamin D, high BMI, and pediatric-onset MS.
    Neurology. 2017;88:1623-1629.
    PubMed     Text format     Abstract available


  109. NUNLEY KA, Leckie RL, Orchard TJ, Costacou T, et al
    Physical activity and hippocampal volume in middle-aged patients with type 1 diabetes.
    Neurology. 2017;88:1564-1570.
    PubMed     Text format     Abstract available


  110. MADDISON P, Gozzard P, Grainge MJ, Lang B, et al
    Long-term survival in paraneoplastic Lambert-Eaton myasthenic syndrome.
    Neurology. 2017;88:1334-1339.
    PubMed     Text format     Abstract available


    March 2017
  111. LANDI D, De Rossi N, Zagaglia S, Scarpazza C, et al
    No evidence of beneficial effects of plasmapheresis in natalizumab-associated PML.
    Neurology. 2017;88:1144-1152.
    PubMed     Text format     Abstract available


  112. MARRIE RA, Salter A, Tyry T, Cutter GR, et al
    High hypothetical interest in physician-assisted death in multiple sclerosis.
    Neurology. 2017 Mar 15. pii: 10.1212/WNL.0000000000003831.
    PubMed     Text format     Abstract available


  113. ABSINTA M, Cortese IC, Vuolo L, Nair G, et al
    Leptomeningeal gadolinium enhancement across the spectrum of chronic neuroinflammatory diseases.
    Neurology. 2017 Mar 10. pii: 10.1212/WNL.0000000000003820.
    PubMed     Text format     Abstract available


  114. TORRES-VEGA E, Mancheno N, Cebrian-Silla A, Herranz-Perez V, et al
    Netrin-1 receptor antibodies in thymoma-associated neuromyotonia with myasthenia gravis.
    Neurology. 2017 Mar 1. pii: 10.1212/WNL.0000000000003778.
    PubMed     Text format     Abstract available


    February 2017
  115. NASH RA, Hutton GJ, Racke MK, Popat U, et al
    High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS.
    Neurology. 2017;88:842-852.
    PubMed     Text format     Abstract available


  116. KUHLE J, Nourbakhsh B, Grant D, Morant S, et al
    Serum neurofilament is associated with progression of brain atrophy and disability in early MS.
    Neurology. 2017;88:826-831.
    PubMed     Text format     Abstract available


  117. SIDHOM Y, Maillart E, Tezenas du Montcel S, Kacem I, et al
    Fast multiple sclerosis progression in North Africans: Both genetics and environment matter.
    Neurology. 2017 Feb 24. pii: 10.1212/WNL.0000000000003762.
    PubMed     Text format     Abstract available


  118. MOWRY EM, McArthur JC
    PML in natalizumab-treated multiple sclerosis: Modeling errors and risk miscalculations.
    Neurology. 2017 Feb 22. pii: 10.1212/WNL.0000000000003749.
    PubMed     Text format    


  119. MOLKO N, Simon O, Guyon D, Biron A, et al
    Zika virus infection and myasthenia gravis: Report of 2 cases.
    Neurology. 2017 Feb 10. pii: 10.1212/WNL.0000000000003697.
    PubMed     Text format    


  120. EIJLERS AJ, Meijer KA, Wassenaar TM, Steenwijk MD, et al
    Increased default-mode network centrality in cognitively impaired multiple sclerosis patients.
    Neurology. 2017 Feb 8. pii: 10.1212/WNL.0000000000003689.
    PubMed     Text format     Abstract available


  121. BARTON J, Hardy TA, Riminton S, Reddel SW, et al
    Tumefactive demyelination following treatment for relapsing multiple sclerosis with alemtuzumab.
    Neurology. 2017 Feb 8. pii: 10.1212/WNL.0000000000003694.
    PubMed     Text format    


  122. BODINI B, Calabresi PA
    From neurofilament research to multiple sclerosis clinical practice: Where do we stand?
    Neurology. 2017 Feb 1. pii: 10.1212/WNL.0000000000003676.
    PubMed     Text format    


  123. FILLI L, Zorner B, Kapitza S, Reuter K, et al
    Monitoring long-term efficacy of fampridine in gait-impaired patients with multiple sclerosis.
    Neurology. 2017 Feb 1. pii: 10.1212/WNL.0000000000003656.
    PubMed     Text format     Abstract available


  124. BENNETT SE
    Fampridine: Long-term benefits in walking in multiple sclerosis.
    Neurology. 2017 Feb 1. pii: 10.1212/WNL.0000000000003677.
    PubMed     Text format    


    January 2017
  125. SANDERS DB, Wolfe GI, Narayanaswami P
    Author response: International consensus guidance for management of myasthenia gravis: Executive summary.
    Neurology. 2017;88:505-506.
    PubMed     Text format    


  126. LI HF, Xie Y, Hong Y
    Letter re: International consensus guidance for management of myasthenia gravis: Executive summary.
    Neurology. 2017;88:505.
    PubMed     Text format    


  127. PASNOOR M
    Author response: A randomized controlled trial of methotrexate for patients with generalized myasthenia gravis.
    Neurology. 2017;88:417-418.
    PubMed     Text format    


  128. KELKAR P
    Letter re: A randomized controlled trial of methotrexate for patients with generalized myasthenia gravis.
    Neurology. 2017;88:417.
    PubMed     Text format    


  129. HECKMANN JM, Bateman K
    Letter re: A randomized controlled trial of methotrexate for patients with generalized myasthenia gravis.
    Neurology. 2017;88:417.
    PubMed     Text format    


  130. SCHEIBE F, Pruss H, Mengel AM, Kohler S, et al
    Bortezomib for treatment of therapy-refractory anti-NMDA receptor encephalitis.
    Neurology. 2017;88:366-370.
    PubMed     Text format     Abstract available


  131. MAAROUF A, Audoin B, Pariollaud F, Gherib S, et al
    Increased total sodium concentration in gray matter better explains cognition than atrophy in MS.
    Neurology. 2017;88:289-295.
    PubMed     Text format     Abstract available


  132. BARGIELA D, Bianchi MT, Westover MB, Chibnik LB, et al
    Selection of first-line therapy in multiple sclerosis using risk-benefit decision analysis.
    Neurology. 2017 Jan 13. pii: 10.1212/WNL.0000000000003612.
    PubMed     Text format     Abstract available


  133. BUTTON J, Al-Louzi O, Lang A, Bhargava P, et al
    Disease-modifying therapies modulate retinal atrophy in multiple sclerosis: A retrospective study.
    Neurology. 2017 Jan 11. pii: 10.1212/WNL.0000000000003582.
    PubMed     Text format     Abstract available


  134. MASSEY TH, Smith R, Sadiq S, Overton C, et al
    Rescue of severe brain and cervical cord IRIS by restarting natalizumab in a pregnant MS patient.
    Neurology. 2017 Jan 11. pii: 10.1212/WNL.0000000000003604.
    PubMed     Text format    


  135. DO LD, Chanson E, Desestret V, Joubert B, et al
    Characteristics in limbic encephalitis with anti-adenylate kinase 5 autoantibodies.
    Neurology. 2017 Jan 6. pii: 10.1212/WNL.0000000000003586.
    PubMed     Text format     Abstract available


    December 2016
  136. URUHA A, Nishikawa A, Tsuburaya RS, Hamanaka K, et al
    Sarcoplasmic MxA expression: A valuable marker of dermatomyositis.
    Neurology. 2016 Dec 30. pii: 10.1212/WNL.0000000000003568.
    PubMed     Text format     Abstract available


  137. ROCCA MA, Battaglini M, Benedict RH, De Stefano N, et al
    Brain MRI atrophy quantification in MS: From methods to clinical application.
    Neurology. 2016 Dec 16. pii: 10.1212/WNL.0000000000003542.
    PubMed     Text format     Abstract available


  138. GOEDEE HS, van der Pol WL, van Asseldonk JH, Franssen H, et al
    Diagnostic value of sonography in treatment-naive chronic inflammatory neuropathies.
    Neurology. 2016 Dec 7. pii: 10.1212/WNL.0000000000003483.
    PubMed     Text format     Abstract available


    November 2016
  139. NIELSEN NM, Munger KL, Koch-Henriksen N, Hougaard DM, et al
    Neonatal vitamin D status and risk of multiple sclerosis: A population-based case-control study.
    Neurology. 2016 Nov 30. pii: 10.1212/WNL.0000000000003454.
    PubMed     Text format     Abstract available


  140. KIM DD, Budhram A, Pelz D, MacDonald M, et al
    Teaching NeuroImages: Orbital infarction syndrome from giant cell arteritis.
    Neurology. 2016;87:e269.
    PubMed     Text format    


  141. TENSER RB, Truini A, Cruccu G
    A dual concurrent mechanism explains trigeminal neuralgia in patients with multiple sclerosis.
    Neurology. 2016;87:2385-2386.
    PubMed     Text format    



  142. Pediatric multiple sclerosis: The 2015 Sydney Carter Award Lecture.
    Neurology. 2016;87:2284.
    PubMed     Text format    


  143. DALE RC, Brenton JN
    Maternal autoimmunity is a risk factor for common neurologic diseases of childhood.
    Neurology. 2016 Nov 16. pii: 10.1212/WNL.0000000000003440.
    PubMed     Text format    


  144. BEADNALL HN, Gill AJ, Riminton S, Barnett MH, et al
    Virus-related Merkel cell carcinoma complicating fingolimod treatment for multiple sclerosis.
    Neurology. 2016 Nov 16. pii: 10.1212/WNL.0000000000003434.
    PubMed     Text format    



  145. Pediatric multiple sclerosis: Conventional first-line treatment and general management.
    Neurology. 2016;87:2068.
    PubMed     Text format    


  146. DIMACHKIE MM, Abuzinadah AR, Barohn RJ, Oskarsson B, et al
    Myasthenia gravis exacerbation after discontinuing mycophenolate: A single-center cohort study.
    Neurology. 2016;87:2067-2068.
    PubMed     Text format    


  147. ESHAGHI A, Wottschel V, Cortese R, Calabrese M, et al
    Gray matter MRI differentiates neuromyelitis optica from multiple sclerosis using random forest.
    Neurology. 2016 Nov 2. pii: 10.1212/WNL.0000000000003395.
    PubMed     Text format     Abstract available


    October 2016
  148. BOLDINGH MI, Maniaol AH, Brunborg C, Weedon-Fekjaer H, et al
    Increased risk for clinical onset of myasthenia gravis during the postpartum period.
    Neurology. 2016 Oct 21. pii: 10.1212/WNL.0000000000003339.
    PubMed     Text format     Abstract available


  149. BOURDETTE D
    Rituximab for treating multiple sclerosis: Off-label but on target.
    Neurology. 2016 Oct 19. pii: 10.1212/WNL.0000000000003345.
    PubMed     Text format    


  150. SALZER J, Svenningsson R, Alping P, Novakova L, et al
    Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy.
    Neurology. 2016 Oct 19. pii: 10.1212/WNL.0000000000003331.
    PubMed     Text format     Abstract available


  151. GIOVANNONI G, Cohen JA, Coles AJ, Hartung HP, et al
    Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients.
    Neurology. 2016 Oct 12. pii: 10.1212/WNL.0000000000003319.
    PubMed     Text format     Abstract available


    September 2016
  152. DORANS KS, Massa J, Chitnis T, Ascherio A, et al
    Physical activity and the incidence of multiple sclerosis.
    Neurology. 2016 Sep 28. pii: 10.1212/WNL.0000000000003260.
    PubMed     Text format     Abstract available


  153. KANTOR D, Sotirchos ES, Calabresi PA
    Safety and immunologic effects of high- vs low-dose cholecalciferol in multiple sclerosis.
    Neurology. 2016;87:1424.
    PubMed     Text format    


  154. COTTER J, Firth J, Enzinger C, Kontopantelis E, et al
    Social cognition in multiple sclerosis: A systematic review and meta-analysis.
    Neurology. 2016 Sep 21. pii: 10.1212/WNL.0000000000003236.
    PubMed     Text format     Abstract available


  155. KELLY DM, Kelleher EM, O'Shea A, Sweeney B, et al
    Teaching Video NeuroImages: Primary writing tremor: Lessons from a patient with multiple sclerosis.
    Neurology. 2016;87:e131.
    PubMed     Text format    


  156. BOVE R, White CC, Fitzgerald KC, Chitnis T, et al
    Hormone therapy use and physical quality of life in postmenopausal women with multiple sclerosis.
    Neurology. 2016 Sep 7. pii: 10.1212/WNL.0000000000003176.
    PubMed     Text format     Abstract available


  157. VOSKUHL R, Patti F
    Hormone replacement in menopausal women with multiple sclerosis: Looking back, thinking forward.
    Neurology. 2016 Sep 7. pii: 10.1212/WNL.0000000000003189.
    PubMed     Text format    


  158. PANZER JA, Lyons JA
    Autoimmune encephalitis in the age of neuronal surface antigens.
    Neurology. 2016 Sep 2. pii: 10.1212/WNL.0000000000003187.
    PubMed     Text format    


  159. ARNOLD DL, Fisher E, Brinar VV, Cohen JA, et al
    Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon beta-1a in MS.
    Neurology. 2016 Sep 2. pii: 10.1212/WNL.0000000000003169.
    PubMed     Text format     Abstract available


    August 2016
  160. SOLOMON AJ, Bourdette DN, Cross AH, Applebee A, et al
    The contemporary spectrum of multiple sclerosis misdiagnosis: A multicenter study.
    Neurology. 2016 Aug 31. pii: 10.1212/WNL.0000000000003152.
    PubMed     Text format     Abstract available


  161. GHEZZI A, Amato MP, Makhani N, Shreiner T, et al
    Pediatric multiple sclerosis: Conventional first-line treatment and general management.
    Neurology. 2016;87.
    PubMed     Text format     Abstract available


  162. BANWELL B, Arnold DL, Tillema JM, Rocca MA, et al
    MRI in the evaluation of pediatric multiple sclerosis.
    Neurology. 2016;87.
    PubMed     Text format     Abstract available


  163. AMATO MP, Krupp LB, Charvet LE, Penner I, et al
    Pediatric multiple sclerosis: Cognition and mood.
    Neurology. 2016;87.
    PubMed     Text format     Abstract available


  164. WALDMAN A, Ness J, Pohl D, Simone IL, et al
    Pediatric multiple sclerosis: Clinical features and outcome.
    Neurology. 2016;87.
    PubMed     Text format     Abstract available


  165. HINTZEN RQ, Dale RC, Neuteboom RF, Mar S, et al
    Pediatric acquired CNS demyelinating syndromes: Features associated with multiple sclerosis.
    Neurology. 2016;87.
    PubMed     Text format     Abstract available


  166. KRUPP LB, Rintell D, Charvet LE, Milazzo M, et al
    Pediatric multiple sclerosis: Perspectives from adolescents and their families.
    Neurology. 2016;87.
    PubMed     Text format     Abstract available


  167. CHITNIS T, Ghezzi A, Bajer-Kornek B, Boyko A, et al
    Pediatric multiple sclerosis: Escalation and emerging treatments.
    Neurology. 2016;87.
    PubMed     Text format     Abstract available



  168. CD62L is not a reliable biomarker for predicting PML risk in natalizumab-treated R-MS patients.
    Neurology. 2016;87:960.
    PubMed     Text format    


  169. SCHWAB N, Schneider-Hohendorf T, Wiendl H, Cahir-McFarland E, et al
    CD62L is not a reliable biomarker for predicting PML risk in natalizumab-treated R-MS patients.
    Neurology. 2016;87:958-9.
    PubMed     Text format    


  170. CAHIR-MCFARLAND E, Ransohoff RM, Lieberman L, Plavina T, et al
    CD62L is not a reliable biomarker for predicting PML risk in natalizumab-treated R-MS patients. Author Response.
    Neurology. 2016;87:958-9.
    PubMed     Text format    


  171. BANWELL B
    Pediatric multiple sclerosis: The 2015 Sydney Carter Award Lecture.
    Neurology. 2016;87:822-6.
    PubMed     Text format    


  172. KHALIL M, Salzer J
    CSF neurofilament light: A universal risk biomarker in multiple sclerosis?
    Neurology. 2016 Aug 12. pii: 10.1212/WNL.0000000000003107.
    PubMed     Text format    



  173. Journal Club: Effect of comorbidity on mortality in multiple sclerosis.
    Neurology. 2016;87:646.
    PubMed     Text format    


  174. JONES DE, Sutliff MH, Halper J, Armstrong MJ, et al
    Summary of comprehensive systematic review: Rehabilitation in multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
    Neurology. 2016;87:646.
    PubMed     Text format    


  175. QUIROGA AC, Sabatino JJ Jr, Zee DS, Gold DR, et al
    Teaching Video NeuroImages: The hopping lid twitch in myasthenia gravis.
    Neurology. 2016;87:e55.
    PubMed     Text format    


    July 2016
  176. PURCHIARONI F, Salvetti M, Buscarinu MC, Annibale B, et al
    Eosinophilic gastroenteritis in a woman with multiple sclerosis on dimethyl fumarate.
    Neurology. 2016 Jul 27. pii: 10.1212/WNL.0000000000003045.
    PubMed     Text format    


  177. BENOIT A, Durand-Dubief F, Amato MP, Portaccio E, et al
    History of multiple sclerosis in 2 successive pregnancies: A French and Italian cohort.
    Neurology. 2016 Jul 27. pii: 10.1212/WNL.0000000000003036.
    PubMed     Text format     Abstract available


  178. GILMORE W, Airas L
    Successive pregnancies in multiple sclerosis.
    Neurology. 2016 Jul 27. pii: 10.1212/WNL.0000000000003039.
    PubMed     Text format    


  179. SIU R, Bukhari W, Todd A, Gunn W, et al
    Acute Zika infection with concurrent onset of Guillain-Barre Syndrome.
    Neurology. 2016 Jul 27. pii: 10.1212/WNL.0000000000003038.
    PubMed     Text format    


  180. GOLAN D, Miller A, Sotirchos ES, Bhargava P, et al
    Safety and immunologic effects of high- vs low-dose cholecalciferol in multiple sclerosis.
    Neurology. 2016;87:446.
    PubMed     Text format    


  181. AVASARALA J, Sotirchos ES, Bhargava P, Calabresi PA, et al
    Safety and immunologic effects of high- vs low-dose cholecalciferol in multiple sclerosis.
    Neurology. 2016;87:445-6.
    PubMed     Text format    


  182. PREZIOSA P, Comi G, Filippi M
    Optic neuritis in multiple sclerosis: Looking from a patient's eyes.
    Neurology. 2016;87:338-9.
    PubMed     Text format    


  183. FERREIRA DA SILVA IR, Frontera JA, Moreira do Nascimento OJ
    News from the battlefront: Zika virus-associated Guillain-BarrE Syndrome in Brazil.
    Neurology. 2016 Jul 15. pii: 10.1212/WNL.0000000000003024.
    PubMed     Text format    


  184. MILLER AE, Pelletier D
    Multiple sclerosis: Rapid diagnosis or right diagnosis?
    Neurology. 2016 Jul 15. pii: 10.1212/WNL.0000000000002994.
    PubMed     Text format    


  185. BROWNLEE WJ, Swanton JK, Miszkiel KA, Miller DH, et al
    Should the symptomatic region be included in dissemination in space in MRI criteria for MS?
    Neurology. 2016 Jul 15. pii: 10.1212/WNL.0000000000002975.
    PubMed     Text format     Abstract available


  186. BARNETT C, Bril V, Kapral M, Kulkarni A, et al
    Development and validation of the Myasthenia Gravis Impairment Index.
    Neurology. 2016 Jul 8. pii: 10.1212/WNL.0000000000002971.
    PubMed     Text format     Abstract available


  187. DALE RC, Lim M
    The origins and progression of CNS autoimmunity: Nature, nurture, and tumor.
    Neurology. 2016 Jul 6. pii: 10.1212/WNL.0000000000002959.
    PubMed     Text format    


    June 2016
  188. WANG G, Marrie RA, Salter AR, Fox R, et al
    Health insurance affects the use of disease-modifying therapy in multiple sclerosis.
    Neurology. 2016 Jun 29. pii: 10.1212/WNL.0000000000002887.
    PubMed     Text format     Abstract available


  189. SANDERS DB, Wolfe GI, Benatar M, Evoli A, et al
    International consensus guidance for management of myasthenia gravis: Executive summary.
    Neurology. 2016 Jun 29. pii: 10.1212/WNL.0000000000002790.
    PubMed     Text format     Abstract available


  190. LEHMANN-HORN K, Penkert H, Grein P, Leppmeier U, et al
    PML during dimethyl fumarate treatment of multiple sclerosis: How does lymphopenia matter?
    Neurology. 2016 Jun 24. pii: 10.1212/WNL.0000000000002900.
    PubMed     Text format    


  191. DE FLON P, Gunnarsson M, Laurell K, Soderstrom L, et al
    Reduced inflammation in relapsing-remitting multiple sclerosis after therapy switch to rituximab.
    Neurology. 2016 Jun 17. pii: 10.1212/WNL.0000000000002832.
    PubMed     Text format     Abstract available


  192. DRACHMAN DB
    Methotrexate for patients with generalized myasthenia gravis.
    Neurology. 2016 Jun 15. pii: 10.1212/WNL.0000000000002818.
    PubMed     Text format    


  193. PASNOOR M, He J, Herbelin L, Burns TM, et al
    A randomized controlled trial of methotrexate for patients with generalized myasthenia gravis.
    Neurology. 2016 Jun 15. pii: 10.1212/WNL.0000000000002795.
    PubMed     Text format     Abstract available


  194. BUTZKUEVEN H, Calabresi PA
    Is my MS patient failing treatment?
    Neurology. 2016 Jun 15. pii: 10.1212/WNL.0000000000002851.
    PubMed     Text format    


    May 2016
  195. KARAMYAN A, Sellner J
    Journal Club: Effect of comorbidity on mortality in multiple sclerosis.
    Neurology. 2016;86:e228-30.
    PubMed     Text format    


  196. KOELMAN DL, Chahin S, Mar SS, Venkatesan A, et al
    Acute disseminated encephalomyelitis in 228 patients: A retrospective, multicenter US study.
    Neurology. 2016;86:2085-93.
    PubMed     Text format     Abstract available


  197. SENA A, Capela C, Ferret-Sena V, Munger KL, et al
    No association of multiple sclerosis activity and progression with EBV or tobacco use in BENEFIT.
    Neurology. 2016;86:2026.
    PubMed     Text format    


  198. WATERS PJ, Irani SR
    Neurexin-3alpha: A new antibody target in autoimmune encephalitis.
    Neurology. 2016 May 11. pii: 10.1212/WNL.0000000000002781.
    PubMed     Text format    


  199. BUTTMANN M, Seuffert L, Mader U, Toyka KV, et al
    Malignancies after mitoxantrone for multiple sclerosis: A retrospective cohort study.
    Neurology. 2016 May 11. pii: 10.1212/WNL.0000000000002745.
    PubMed     Text format     Abstract available


  200. HYUN JW, Jeong IH, Joung A, Kim SH, et al
    Evaluation of the 2015 diagnostic criteria for neuromyelitis optica spectrum disorder.
    Neurology. 2016;86:1772-9.
    PubMed     Text format     Abstract available


  201. SPATOLA M, Du Pasquier R, Schluep M, Regeniter A, et al
    Serum and CSF GQ1b antibodies in isolated ophthalmologic syndromes.
    Neurology. 2016;86:1780-4.
    PubMed     Text format     Abstract available


  202. KASSAVETIS P, Joseph JB, Francois R, Perloff MD, et al
    Zika virus-associated Guillain-Barre syndrome variant in Haiti.
    Neurology. 2016 May 6. pii: 10.1212/WNL.0000000000002759.
    PubMed     Text format    


  203. TRUINI A, Prosperini L, Calistri V, Fiorelli M, et al
    A dual concurrent mechanism explains trigeminal neuralgia in patients with multiple sclerosis.
    Neurology. 2016 May 4. pii: 10.1212/WNL.0000000000002720.
    PubMed     Text format     Abstract available


  204. VAN SONDEREN A, Schreurs MW, de Bruijn MA, Boukhrissi S, et al
    The relevance of VGKC positivity in the absence of LGI1 and Caspr2 antibodies.
    Neurology. 2016;86:1692-9.
    PubMed     Text format     Abstract available


  205. MELINYSHYN AN, Gofton TE, Schulz V
    Supernumerary phantom limbs in ICU patients with acute inflammatory demyelinating polyneuropathy.
    Neurology. 2016;86:1726-8.
    PubMed     Text format     Abstract available


    April 2016
  206. SUMOWSKI JF, Rocca MA, Leavitt VM, Meani A, et al
    Brain reserve against physical disability progression over 5 years in multiple sclerosis.
    Neurology. 2016 Apr 27. pii: 10.1212/WNL.0000000000002702.
    PubMed     Text format     Abstract available


  207. DE LOTT LB, Burke JF, Kerber KA, Skolarus LE, et al
    Medicare Part D payments for neurologist-prescribed drugs.
    Neurology. 2016;86:1491-8.
    PubMed     Text format     Abstract available



  208. Quality improvement in neurology: Multiple sclerosis quality measures: Executive summary.
    Neurology. 2016;86:1465.
    PubMed     Text format    


  209. MCDONNELL GV, Bennett A, Rae-Grant A, Bever C, et al
    Quality improvement in neurology: Multiple sclerosis quality measures: Executive summary.
    Neurology. 2016;86:1361.
    PubMed     Text format    


  210. BENNETT A, Rae-Grant A, Bever C
    Author Response.
    Neurology. 2016;86:1361.
    PubMed     Text format    


  211. VOLLMER TL, McCarthy M
    Autoimmune encephalitis: A more treatable tragedy if diagnosed early.
    Neurology. 2016 Apr 1. pii: 10.1212/WNL.0000000000002641.
    PubMed     Text format    


  212. LEE WJ, Lee ST, Byun JI, Sunwoo JS, et al
    Rituximab treatment for autoimmune limbic encephalitis in an institutional cohort.
    Neurology. 2016 Apr 1. pii: 10.1212/WNL.0000000000002635.
    PubMed     Text format     Abstract available


    March 2016
  213. HODEL J, Darchis C, Outteryck O, Verclytte S, et al
    Punctate pattern: A promising imaging marker for the diagnosis of natalizumab-associated PML.
    Neurology. 2016 Mar 23. pii: 10.1212/WNL.0000000000002586.
    PubMed     Text format     Abstract available


  214. HOBSON-WEBB LD
    Comment: Is 3,4-DAP a new option in treating MuSK MG?
    Neurology. 2016;86:1071.
    PubMed     Text format    


  215. GRANT WB, Riise T
    Multiple sclerosis: A lifestyle disease?
    Neurology. 2016 Mar 9. pii: 10.1212/WNL.0000000000002487.
    PubMed     Text format    


  216. BERRIGAN LI, Fisk JD, Patten SB, Tremlett H, et al
    Health-related quality of life in multiple sclerosis: Direct and indirect effects of comorbidity.
    Neurology. 2016 Mar 9. pii: 10.1212/WNL.0000000000002564.
    PubMed     Text format     Abstract available


  217. MARRIE RA, Patten SB, Tremlett H, Wolfson C, et al
    Sex differences in comorbidity at diagnosis of multiple sclerosis: A population-based study.
    Neurology. 2016 Mar 9. pii: 10.1212/WNL.0000000000002481.
    PubMed     Text format     Abstract available


  218. O'CONNOR P, Comi G, Freedman MS, Miller AE, et al
    Long-term safety and efficacy of teriflunomide: Nine-year follow-up of the randomized TEMSO study.
    Neurology. 2016;86:920-30.
    PubMed     Text format     Abstract available


  219. ZHANG T, Tremlett H, Leung S, Zhu F, et al
    Examining the effects of comorbidities on disease-modifying therapy use in multiple sclerosis.
    Neurology. 2016 Mar 4. pii: 10.1212/WNL.0000000000002543.
    PubMed     Text format     Abstract available


  220. GONZALEZ-PEREZ P, Correia M, Capizzano AA, Adams HP, et al
    Isolated cortical vein thrombosis in autoimmune polyglandular syndrome type 2.
    Neurology. 2016 Mar 2. pii: 10.1212/WNL.0000000000002530.
    PubMed     Text format    


  221. DALAKAS MC, Gooch C
    Close to the node but far enough: What nodal antibodies tell us about CIDP and its therapies.
    Neurology. 2016;86:796-7.
    PubMed     Text format    


  222. DEVAUX JJ, Miura Y, Fukami Y, Inoue T, et al
    Neurofascin-155 IgG4 in chronic inflammatory demyelinating polyneuropathy.
    Neurology. 2016;86:800-7.
    PubMed     Text format     Abstract available


    February 2016
  223. BARBIN L, Rousseau C, Jousset N, Casey R, et al
    Comparative efficacy of fingolimod vs natalizumab: A French multicenter observational study.
    Neurology. 2016;86:771-8.
    PubMed     Text format     Abstract available


  224. LOPEZ-CHIRIBOGA AS, Komorowski L, Kumpfel T, Probst C, et al
    Metabotropic glutamate receptor type 1 autoimmunity: Clinical features and treatment outcomes.
    Neurology. 2016 Feb 17. pii: 10.1212/WNL.0000000000002476.
    PubMed     Text format     Abstract available


  225. MARRIE RA, Miller A, Sormani MP, Thompson A, et al
    The challenge of comorbidity in clinical trials for multiple sclerosis.
    Neurology. 2016 Feb 17. pii: 10.1212/WNL.0000000000002471.
    PubMed     Text format     Abstract available


  226. DILOKTHORNSAKUL P, Valuck RJ, Nair KV, Corboy JR, et al
    Multiple sclerosis prevalence in the United States commercially insured population.
    Neurology. 2016 Feb 17. pii: 10.1212/WNL.0000000000002469.
    PubMed     Text format     Abstract available


  227. EVOLI A, Alboini PE, Damato V, Iorio R, et al
    3,4-diaminopyridine may improve myasthenia gravis with MuSK antibodies.
    Neurology. 2016 Feb 12. pii: 10.1212/WNL.0000000000002466.
    PubMed     Text format    


  228. MARRIE RA, Miller A, Sormani MP, Thompson A, et al
    Recommendations for observational studies of comorbidity in multiple sclerosis.
    Neurology. 2016 Feb 10. pii: 10.1212/WNL.0000000000002474.
    PubMed     Text format     Abstract available


  229. OSKARSSON B, Rocke DM, Dengel K, Richman DP, et al
    Myasthenia gravis exacerbation after discontinuing mycophenolate: A single-center cohort study.
    Neurology. 2016 Feb 5. pii: 10.1212/WNL.0000000000002405.
    PubMed     Text format     Abstract available


  230. CORTESE I, Ohayon J, Fenton K, Lee CC, et al
    Cutaneous adverse events in multiple sclerosis patients treated with daclizumab.
    Neurology. 2016 Feb 3. pii: 10.1212/WNL.0000000000002417.
    PubMed     Text format     Abstract available


  231. TAN CT, Mao Z, Qiu W, Hu X, et al
    International consensus diagnostic criteria for neuromyelitis optica spectrum disorders.
    Neurology. 2016;86:491-2.
    PubMed     Text format    


  232. HAN C, Huang J, Waxman SG
    Sodium channel Nav1.8: Emerging links to human disease.
    Neurology. 2016;86:473-83.
    PubMed     Text format     Abstract available


    January 2016
  233. SHEIKH Z, Jain S, Hillen M
    Acute retinal necrosis in multiple sclerosis: A neuroimmunologic challenge!
    Neurology. 2016 Jan 29. pii: 10.1212/WNL.0000000000002450.
    PubMed     Text format    


  234. NERRANT E, Fourcade C, Coulette S, Lechiche C, et al
    Teaching NeuroImages: Extensive vasogenic edema in Bickerstaff brainstem encephalitis.
    Neurology. 2016;86:e38-9.
    PubMed     Text format    


  235. SOUZA PV, Pinto WB, Oliveira AS
    Teaching NeuroImages: Longitudinally extensive transverse myelitis in MELAS.
    Neurology. 2016;86:e37.
    PubMed     Text format    


  236. PRASAD S, Halmagyi GM
    A new test for ocular myasthenia gravis? OMG!
    Neurology. 2016 Jan 20. pii: 10.1212/WNL.0000000000002380.
    PubMed     Text format    


  237. VALKO Y, Rosengren SM, Jung HH, Straumann D, et al
    Ocular vestibular evoked myogenic potentials as a test for myasthenia gravis.
    Neurology. 2016 Jan 20. pii: 10.1212/WNL.0000000000002383.
    PubMed     Text format     Abstract available


  238. BOURRE B, Gueudry J, Lefaucheur R, Borden A, et al
    Progressive outer retinal necrosis in a multiple sclerosis patient on natalizumab.
    Neurology. 2016;86:312-3.
    PubMed     Text format    


  239. LINCOLN MR, Schneider R, Hohol M
    Clinical Reasoning: A 34-year-old man with headache, diplopia, and hemiparesis.
    Neurology. 2016;86:e24-8.
    PubMed     Text format    


  240. CHITNIS T, Ness J, Krupp L, Waubant E, et al
    Clinical features of neuromyelitis optica in children: US Network of Pediatric MS Centers report.
    Neurology. 2016;86:245-52.
    PubMed     Text format     Abstract available


  241. BODINI B, Chard D, Altmann DR, Tozer D, et al
    White and gray matter damage in primary progressive MS: The chicken or the egg?
    Neurology. 2016;86:170-6.
    PubMed     Text format     Abstract available


  242. WAXMAN SG, Kantarci O
    The cerebellar channelopathy of multiple sclerosis.
    Neurology. 2016 Jan 6. pii: 10.1212/WNL.0000000000002338.
    PubMed     Text format    


  243. ROOSTAEI T, Sadaghiani S, Park MT, Mashhadi R, et al
    Channelopathy-related SCN10A gene variants predict cerebellar dysfunction in multiple sclerosis.
    Neurology. 2016 Jan 6. pii: 10.1212/WNL.0000000000002326.
    PubMed     Text format     Abstract available


  244. NOUR MM, Nakashima I, Coutinho E, Woodhall M, et al
    Pregnancy outcomes in aquaporin-4-positive neuromyelitis optica spectrum disorder.
    Neurology. 2016;86:79-87.
    PubMed     Text format     Abstract available


  245. UZGIL B, Sherr EH
    Neuroimaging in Aicardi-Goutieres syndrome: Biomarkers for a progressive encephalopathy.
    Neurology. 2016;86:15-6.
    PubMed     Text format    


    December 2015
  246. SOTIRCHOS ES, Bhargava P, Eckstein C, Van Haren K, et al
    Safety and immunologic effects of high- vs low-dose cholecalciferol in multiple sclerosis.
    Neurology. 2015 Dec 30. pii: 10.1212/WNL.0000000000002316.
    PubMed     Text format     Abstract available


  247. KIM JK, Kim BJ, Shin HY, Shin KJ, et al
    Acute bulbar palsy as a variant of Guillain-Barre syndrome.
    Neurology. 2015 Dec 30. pii: 10.1212/WNL.0000000000002256.
    PubMed     Text format     Abstract available


  248. LIEBERMAN LA, Zeng W, Singh C, Wang W, et al
    CD62L is not a reliable biomarker for predicting PML risk in natalizumab-treated R-MS patients.
    Neurology. 2015 Dec 30. pii: 10.1212/WNL.0000000000002314.
    PubMed     Text format     Abstract available


  249. MARRIE RA, Fisk JD, Tremlett H, Wolfson C, et al
    Differences in the burden of psychiatric comorbidity in MS vs the general population.
    Neurology. 2015;85:1972-9.
    PubMed     Text format     Abstract available


    November 2015
  250. LAVI E, Gilden D, Nagel M, White T, et al
    Prevalence and distribution of VZV in temporal arteries of patients with giant cell arteritis.
    Neurology. 2015;85:1914-5.
    PubMed     Text format    


  251. HASELKORN JK, Hughes C, Rae-Grant A, Henson LJ, et al
    Summary of comprehensive systematic review: Rehabilitation in multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
    Neurology. 2015;85:1896-903.
    PubMed     Text format     Abstract available


  252. LA PIANA R, Uggetti C, Roncarolo F, Vanderver A, et al
    Neuroradiologic patterns and novel imaging findings in Aicardi-Goutieres syndrome.
    Neurology. 2015 Nov 18. pii: 10.1212/WNL.0000000000002228.
    PubMed     Text format     Abstract available


  253. MABRAY MC, Cha S
    CNS angiitis as a brain tumor mimic with a branching vascular abnormality on T2* MRI.
    Neurology. 2015;85:1819-20.
    PubMed     Text format    


  254. BRADSHAW MJ, Pawate S, Lennon VA, Bloch KC, et al
    Herpes simplex virus 1 encephalitis associated with voltage-gated calcium channel autoimmunity.
    Neurology. 2015 Nov 13. pii: 10.1212/WNL.0000000000002218.
    PubMed     Text format    


  255. HARTUNG DM, Bourdette DN, Ahmed S, Whitham RH, et al
    Author response.
    Neurology. 2015;85:1728.
    PubMed     Text format    


  256. RITTENHOUSE BE
    The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: too big to fail?
    Neurology. 2015;85:1727-8.
    PubMed     Text format    


  257. HARTUNG DM, Bourdette DN, Whitham RH
    Author response.
    Neurology. 2015;85:1727.
    PubMed     Text format    


  258. RITTENHOUSE BE
    The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: too big to fail?
    Neurology. 2015;85:1727-8.
    PubMed     Text format    


  259. DE STEFANO N, Stromillo ML, Giorgio A, Battaglini M, et al
    Long-term assessment of no evidence of disease activity in relapsing-remitting MS.
    Neurology. 2015;85:1722-3.
    PubMed     Text format    


  260. DEBS R, Maillart E, Fahed R, Papeix C, et al
    Extensive brain demyelinating lesions under natalizumab: The role of anti-natalizumab antibodies.
    Neurology. 2015;85:1630-2.
    PubMed     Text format    


    October 2015
  261. LOUAPRE C, Govindarajan ST, Gianni C, Langkammer C, et al
    Beyond focal cortical lesions in MS: An in vivo quantitative and spatial imaging study at 7T.
    Neurology. 2015 Oct 14. pii: 10.1212/WNL.0000000000002106.
    PubMed     Text format     Abstract available


  262. SYMMONDS M, Leite MI, Schulz UG
    Author's Response:.
    Neurology. 2015;85:1263.
    PubMed     Text format    


  263. TAIEB G, Labauge P
    Anti-MOG antibodies with longitudinally extensive transverse myelitis preceded by CLIPPERS.
    Neurology. 2015;85:1262-3.
    PubMed     Text format    


  264. BOVE R, Malik MT, Diaz-Cruz C, Chua A, et al
    The 2D:4D ratio, a proxy for prenatal androgen levels, differs in men with and without MS.
    Neurology. 2015;85:1209-13.
    PubMed     Text format     Abstract available


  265. LUCAS RM, Banwell B
    Do prenatal sex hormones modulate MS risk?
    Neurology. 2015;85:1193-4.
    PubMed     Text format    


    September 2015
  266. LIU Y, Fu Y, Schoonheim MM, Zhang N, et al
    Structural MRI substrates of cognitive impairment in neuromyelitis optica.
    Neurology. 2015 Sep 30. pii: 10.1212/WNL.0000000000002067.
    PubMed     Text format     Abstract available


  267. LABINER DM
    William A. Sibley, MD (1925-2015).
    Neurology. 2015;85:1016.
    PubMed     Text format    


  268. URREA-MENDOZA E, Kanter D, Revilla FJ, Dornoff E, et al
    Stiff-arm syndrome.
    Neurology. 2015;85:1088-9.
    PubMed     Text format    


    August 2015
  269. SORMANI MP, Evangelou N
    New imaging language skills required in MS.
    Neurology. 2015 Aug 28. pii: 10.1212/WNL.0000000000001978.
    PubMed     Text format    


  270. GASPARD N, Foreman BP, Alvarez V, Cabrera Kang C, et al
    New-onset refractory status epilepticus: Etiology, clinical features, and outcome.
    Neurology. 2015 Aug 21. pii: 10.1212/WNL.0000000000001940.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Autoimmune Disorders is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: